AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27458945 — intervention group
Group type: COMPARATOR
Intervention: SRS plus WBRT
Number of subjects: 213
Study 25559834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 25559834 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 25559834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 22763666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin
Number of subjects: 57
Study 22763666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 20007948 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 124
Study 20007948 — intervention group
Group type: COMPARATOR
Intervention: Control group (selective arterial glucose measurements)
Number of subjects: 124
Study 17387356 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) principles and methods
Number of subjects: 0
Study 17387356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional techniques
Number of subjects: 0
Study 17387356 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines in interventional pain management
Number of subjects: 0
Study 16195625 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan added to conventional treatment (V group)
Number of subjects: 23
Study 16195625 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (C group)
Number of subjects: 23
Study 12269709 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training for pharmacists to provide individualized asthma management services for up to 1 year.
Number of subjects: 330
Study 12269709 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330
Study 10415251 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 76
Study 10415251 — intervention group
Group type: COMPARATOR
Intervention: Sodium sulphate
Number of subjects: 76
Study 7556834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% chlorhexidine gel
Number of subjects: 981
Study 7556834 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 981
Study 7556834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 981
Study 7556834 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel vs combined placebo plus control group
Number of subjects: 981
Study 2288318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitressin (6 or 10 units) administered by subcutaneous injection 30 minutes prior to contrast medium injection
Number of subjects: 60
Study 2288318 — intervention group
Group type: COMPARATOR
Intervention: Routine procedure (laxatives the previous night and NPO the morning of the examination)
Number of subjects: 60
Study 7420549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (4,500R in 28 to 32 days)
Number of subjects: 475
Study 7420549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 475
Study 31006142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hair removal treatment by trained nurses
Number of subjects: 94
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 395
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level smokers
Number of subjects: 395
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and moderate level alcohol drinkers
Number of subjects: 395
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial cancer patients
Number of subjects: 395
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer patients
Number of subjects: 395
Study 28279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower trust in treatment
Number of subjects: 395
Study 26184850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified follow-up protocol with CEA measurements every two months and imaging in case of two CEA rises
Number of subjects: 3223
Study 26184850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified follow-up protocol
Number of subjects: 3223
Study 23991829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Number of subjects: 16
Study 23991829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 16
Study 23991829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21866658 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen Chuanxiongqin Injection (DCI) 10 mL intravenously dripped in 250 mL normal saline, once daily for 7 to 10 days before PCI
Number of subjects: 76
Study 21866658 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen Chuanxiongqin Injection (DCI)
Number of subjects: 76
Study 21866658 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of Western medicine and PCI (Control group)
Number of subjects: 76
Study 19512973 — intervention group
Group type: COMPARATOR
Intervention: Acute ketamine administration (low dose: 75 ng/mL; high dose: 150 ng/mL)
Number of subjects: 86
Study 19512973 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular recreational ketamine users
Number of subjects: 86
Study 19512973 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-naive polydrug controls
Number of subjects: 86
Study 19512973 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-using controls
Number of subjects: 86
Study 16624928 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (a monoclonal antibody to TNF)
Number of subjects: 0
Study 16624928 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (a soluble TNF receptor fusion protein)
Number of subjects: 0
Study 12632029 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients
Number of subjects: 42
Study 12632029 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients with coronary aneurysms
Number of subjects: 42
Study 12632029 — intervention group
Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients without coronary lesions
Number of subjects: 42
Study 12632029 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 10694615 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass plus transmyocardial revascularization (n = 132)
Number of subjects: 263
Study 10694615 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass alone (n = 131)
Number of subjects: 263
Study 9166316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction (600 mmHg maintained until delivery)
Number of subjects: 322
Study 9166316 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vacuum extraction (100 mmHg between contractions)
Number of subjects: 322
Study 9166316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction
Number of subjects: 322
Study 9166316 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vacuum extraction
Number of subjects: 322
Study 9166316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 322
Study 8268901 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive treatment)
Number of subjects: 12483
Study 8268901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 12483
Study 4037442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + 100 mg X kg‐1 X d‐1 of ketoleucine (Group B)
Number of subjects: 29
Study 4037442 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + 200 mg X kg‐1 X d‐1 of ketoleucine (Group C)
Number of subjects: 29
Study 4037442 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Group A)
Number of subjects: 29
Study 31606036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention and implementation plan with coaching support
Number of subjects: 600
Study 31606036 — intervention group
Group type: COMPARATOR
Intervention: Deferred intervention group
Number of subjects: 600
Study 28444716 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (100 mg ibuprofen)
Number of subjects: 0
Study 28444716 — intervention group
Group type: COMPARATOR
Intervention: Hard tablet (reference, 100 mg ibuprofen)
Number of subjects: 0
Study 28444716 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (3 chews)
Number of subjects: 0
Study 28444716 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (8 chews)
Number of subjects: 0
Study 27246676 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Model for Health (MMH) intervention
Number of subjects: 1983
Study 27246676 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1983
Study 24762458 — intervention group
Group type: EXPERIMENTAL
Intervention: Training through an online podcast
Number of subjects: 100
Study 24762458 — intervention group
Group type: COMPARATOR
Intervention: Training through a synopsis
Number of subjects: 100
Study 24762458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods (podcast and synopsis)
Number of subjects: 100
Study 22802437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene promotion and water treatment intervention
Number of subjects: 0
Study 22802437 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of new latrines to intervention schools
Number of subjects: 0
Study 19729583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training (BAT) for 2 hours on weekdays for 3 weeks
Number of subjects: 33
Study 19729583 — intervention group
Group type: COMPARATOR
Intervention: Control Intervention (CI) for 2 hours on weekdays for 3 weeks
Number of subjects: 33
Study 17851995 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention interventions targeting adolescents in and out of school
Number of subjects: 246
Study 17851995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component approach to prevention including programmes based in schools, communities, mass media, and health facilities
Number of subjects: 246
Study 16213034 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication in ADHD/C subjects
Number of subjects: 0
Study 16213034 — intervention group
Group type: COMPARATOR
Intervention: ADHD/C subjects
Number of subjects: 0
Study 16213034 — intervention group
Group type: COMPARATOR
Intervention: ADHD/I subjects
Number of subjects: 0
Study 16213034 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 12371916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 52
Study 12371916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12559061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly group sessions emphasizing food label information
Number of subjects: 92
Study 9581027 — intervention group
Group type: EXPERIMENTAL
Intervention: meso‐2,3‐dimercaptosuccinic acid (DMSA) at a dose of 30 mg kg‐1
Number of subjects: 12
Study 9581027 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L‐2,3‐dimercaptopropane‐1‐sulfonic acid (DMPS) at a dose of 30 mg kg‐1
Number of subjects: 12
Study 9581027 — intervention group
Group type: COMPARATOR
Intervention: Control (urines)
Number of subjects: 12
Study 8068949 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy arm (T-ALL patients: 26, B-ALL patients: 57)
Number of subjects: 562
Study 8068949 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) arm (T-ALL patients: 35, B-ALL patients: 50)
Number of subjects: 562
Study 8068949 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT) arm (T-ALL patients: 37, B-ALL patients: 71)
Number of subjects: 562
Study 8068949 — intervention group
Group type: EXPERIMENTAL
Intervention: CD10+ T-ALL (31 patients)
Number of subjects: 562
Study 8068949 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell leukemia
Number of subjects: 562
Study 3054619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 127
Study 3054619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 29641294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servoventilation (ASV)
Number of subjects: 18
Study 29641294 — intervention group
Group type: COMPARATOR
Intervention: Supplemental Oxygen
Number of subjects: 18
Study 29641294 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 18
Study 28848332 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA unit treatment
Number of subjects: 408
Study 28848332 — intervention group
Group type: COMPARATOR
Intervention: Conventional acute medical care unit
Number of subjects: 408
Study 25168034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge + Coach Calls (n = 357)
Number of subjects: 1067
Study 25168034 — intervention group
Group type: COMPARATOR
Intervention: Lozenge (n = 356)
Number of subjects: 1067
Study 25168034 — intervention group
Group type: COMPARATOR
Intervention: Coach Calls (n = 354)
Number of subjects: 1067
Study 23299909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ART
Number of subjects: 202
Study 23299909 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART
Number of subjects: 202
Study 21673719 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrient supplementation (MMN)
Number of subjects: 14293
Study 21673719 — intervention group
Group type: COMPARATOR
Intervention: Iron/folic acid supplementation
Number of subjects: 14293
Study 18394129 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Quality-of-life Questionnaire (AQLQ)
Number of subjects: 900
Study 18394129 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form-36 (SF-36)
Number of subjects: 900
Study 18394129 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma attack frequency and hospitalization
Number of subjects: 900
Study 18394129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal symptoms and lung function
Number of subjects: 900
Study 17145534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose three-dimensional conformal radiotherapy (3DCRT) at 66 Gy, 2 Gy/fraction
Number of subjects: 27
Study 14505088 — intervention group
Group type: EXPERIMENTAL
Intervention: Penciclovir (intravenous formulation)
Number of subjects: 1201
Study 14505088 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical penciclovir
Number of subjects: 1201
Study 14505088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famciclovir
Number of subjects: 1201
Study 14505088 — intervention group
Group type: COMPARATOR
Intervention: Penciclovir
Number of subjects: 1201
Study 14505088 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 1201
Study 11093052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and carboplatin (PP group)
Number of subjects: 189
Study 11093052 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, vinblastine and bleomycin (PVB group)
Number of subjects: 189
Study 9371351 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose trimethoprim (10 mg/kg/day)
Number of subjects: 20
Study 9371351 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trimethoprim (20 mg/kg/day)
Number of subjects: 20
Study 1583277 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lens pair (corrected all residual astigmatism)
Number of subjects: 12
Study 1583277 — intervention group
Group type: COMPARATOR
Intervention: Control lens pair (+0.12 DS, considered a placebo)
Number of subjects: 12
Study 31218913 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 45
Study 31218913 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 45
Study 31218913 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 30616699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks
Number of subjects: 26
Study 30616699 — intervention group
Group type: COMPARATOR
Intervention: Nasal normal saline 0.9 per cent for four weeks
Number of subjects: 26
Study 27978426 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified PNF intervention (CampusGANDR)
Number of subjects: 237
Study 27978426 — intervention group
Group type: COMPARATOR
Intervention: Standard PNF intervention (control)
Number of subjects: 237
Study 26328908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 24
Study 26328908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23299370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 16
Study 21426558 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT) plus home exercise program (HEP)
Number of subjects: 192
Study 21426558 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP) alone
Number of subjects: 192
Study 18957933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 522
Study 18957933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 16454480 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement with freedom from grandchild care obligations
Number of subjects: 0
Study 16454480 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued employment while providing grandchild care
Number of subjects: 0
Study 16454480 — intervention group
Group type: COMPARATOR
Intervention: Grandchild care obligations
Number of subjects: 0
Study 14742346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy website (MoodGYM)
Number of subjects: 525
Study 14742346 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation website (BluePages)
Number of subjects: 525
Study 14742346 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (attention placebo)
Number of subjects: 525
Study 11726255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoperfusion-hyperemia (femoral cuff occlusion for 90 seconds at 200 mm Hg followed by 10 seconds of hyperemia)
Number of subjects: 10
Study 11726255 — intervention group
Group type: COMPARATOR
Intervention: Control (40 vertical jumps without femoral artery occlusion)
Number of subjects: 10
Study 9161740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 g propacetamol and 50 mg ketoprofen (group 4)
Number of subjects: 60
Study 9161740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 60
Study 9161740 — intervention group
Group type: COMPARATOR
Intervention: 2 g propacetamol (group 2)
Number of subjects: 60
Study 9161740 — intervention group
Group type: COMPARATOR
Intervention: 50 mg ketoprofen (group 3)
Number of subjects: 60
Study 9161740 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 8203367 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood flow at 419 mL/min
Number of subjects: 16
Study 8203367 — intervention group
Group type: COMPARATOR
Intervention: Low blood flow at 200 mL/min
Number of subjects: 16
Study 8203367 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop flow technique at 419 mL/min
Number of subjects: 16
Study 8203367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood flow technique at 419 mL/min
Number of subjects: 16
Study 2955955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated autologous blood perfusion at 60 ml/min
Number of subjects: 15
Study 2955955 — intervention group
Group type: COMPARATOR
Intervention: Control inflations
Number of subjects: 15
Study 29789919 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach to the hip
Number of subjects: 0
Study 29789919 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach to the hip
Number of subjects: 0
Study 27417703 — intervention group
Group type: EXPERIMENTAL
Intervention: Four times daily insulin (q.i.d) regimen
Number of subjects: 480
Study 27417703 — intervention group
Group type: COMPARATOR
Intervention: Twice daily insulin (b.i.d) regimen
Number of subjects: 480
Study 23396509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (1000-1200 mg/d) for 4 weeks
Number of subjects: 70
Study 23396509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy
Number of subjects: 70
Study 22493916 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group
Number of subjects: 80
Study 22493916 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (Methylcobalamin)
Number of subjects: 80
Study 22493916 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group (within one month after operation)
Number of subjects: 80
Study 22493916 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group (1-3 months after operation)
Number of subjects: 80
Study 19838812 — intervention group
Group type: COMPARATOR
Intervention: Low SPGI (< 25 microg/l)
Number of subjects: 20928
Study 19838812 — intervention group
Group type: COMPARATOR
Intervention: Histologically confirmed atrophic gastritis
Number of subjects: 20928
Study 19838812 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal SPGI (>= 25 microg/l)
Number of subjects: 20928
Study 19838812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SPGI
Number of subjects: 20928
Study 18281262 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 50
Study 18281262 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block (TB)
Number of subjects: 50
Study 18281262 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator vs Twin Block (TB)
Number of subjects: 50
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AF and CHF
Number of subjects: 1321
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe LV dysfunction
Number of subjects: 1321
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients with clinical features (with LV dysfunction)
Number of subjects: 1321
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients with clinical features (without LV dysfunction)
Number of subjects: 1321
Study 15894770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asymptomatic LV dysfunction
Number of subjects: 1321